Hong Kong’s First PIC/S GMP-Certified Stem Cell Production Facility Established at Science Park

HKSTP Hosts Showcase Featuring Clinical Progress from 10 Park Companies and Real-Life Patient Stories

HONG KONG SAR - Media OutReach Newswire - 31 July 2026 - Hong Kong Science and Technology Parks Corporation (HKSTP) today hosted the HKSTP Cell and Gene Therapy (CGT) Showcase 2026 at the Charles K. Kao Auditorium, Hong Kong Science Park, with support from Invest Hong Kong. The event brought together more than 200 representatives from the healthcare, academic, investment and regulatory sectors, both locally and from overseas. A major milestone announced at the event was that HKSTP partner company Hong Kong Regen Medtech Limited (HKRM) has become the first facility in Hong Kong to be recognised by the Pharmacy and Poisons Board of Hong Kong (PPBHK) as an allogeneic mesenchymal stem cell (MSC) PIC/S GMP manufacturing facility, enabling the production of advanced therapy products for clinical trials.

HKSTP hosted the HKSTP CGT Showcase 2026, bringing together local and overseas I&T enterprises, medical experts, researchers, investors and patient representatives to explore the clinical translation and broader development of cell and gene therapy.

Mr Terry Wong, CEO of HKSTP, said in his remarks: "Cell and gene therapy is one of the fastest-growing fields in life and health tech. The establishment of Hong Kong's first stem cell production facility certified to PIC/S GMP standards at Hong Kong Science Park marks a significant milestone for the city's life and health tech ecosystem. The significance of this certification goes far beyond technology alone. It signifies not only that production has met the highest international safety standards, but also that patients and their families can choose locally manufactured cell therapy products with confidence and complete trust. This is a tangible achievement that will enable every Hong Kong citizen to benefit directly. As the orchestrator of Hong Kong's innovation and technology (I&T) ecosystem, HKSTP has been proactively connecting the life and health tech community with partners, investors and academia. Through a diverse range of incubation programmes, we provide our park companies with seed funding, innovation space, world-class infrastructure and regulatory support, helping them overcome challenges in the journey from laboratory research to clinical translation and turning scientific breakthroughs into real therapeutic outcomes for patients. We will continue to drive ecosystem development and fully support local I&T enterprises in bringing research achievements 'Made in Hong Kong' to the global stage."

Hong Kong's First PIC/S GMP Stem Cell Production Facility Bridges a Critical Gap from Research to Clinical Application

One of the highlights of the event was HKRM, an HKSTP partner company, recently obtaining Hong Kong's first PIC/S GMP licence for stem cell production and operating the related manufacturing facility at Hong Kong Science Park, marking a key step in advancing the clinical translation of advanced therapies in Hong Kong. PIC/S GMP is internationally recognised as the gold standard for pharmaceutical manufacturing quality. Facilities must undergo rigorous international assessment to ensure that every batch is produced in a strictly controlled environment.

Mr Stanley Sy, HKRM Co-founder and CEO, said: "HKRM's attainment of Hong Kong's first PIC/S GMP certification for stem cell production marks not only an important milestone in the company's development, but also signifies that Hong Kong now has the critical infrastructure needed to further support the clinical translation of advanced cell therapies. A stringent, internationally recognised manufacturing quality system helps ensure product consistency and traceability, while strengthening the confidence of medical and regulatory authorities in locally manufactured cell-based products. Based at Hong Kong Science Park, HKRM is grateful for the longstanding support of HKSTP. We also look forward to working with research and clinical partners in the Park to bring more promising therapeutic solutions from Hong Kong to the international stage."

Patients, Families and Doctors Share First-hand Stories of the Journey from Cell Banking to Clinical Breakthroughs

The event also featured first-hand experiences from patients, their families and doctors on their treatment journeys. Park company Mononuclear Therapeutics (MonoTx) operates Hong Kong's first AABB-accredited public cord blood bank and haematopoietic stem cell apheresis facility at Hong Kong Science Park, with more than 2,000 cord blood units in storage.

Dr Wendy Cheng, Chief Operating Officer of MonoTx, joined Professor Leung Tak Yeung and Professor Ronald Wang of the Department of Obstetrics and Gynaecology at The Chinese University of Hong Kong (CUHK) to share research findings and patient cases with patient families.

Professor Leung Tak Yeung's team at CUHK is studying a treatment for foetuses with severe alpha-thalassaemia by processing the mother's stem cells through MonoTx and infusing them into the foetus, to investigate whether the foetus can develop immune tolerance to the mother's stem cells and thereby improve clinical outcomes.

Professor Ronald Wang's team is using cord blood to treat neonatal brain injury. Preliminary findings suggest that cord blood infusion within 48 hours of birth may help repair brain injury and improve the child's developmental outcomes later in life.

360 Life Sciences Companies Gather at Hong Kong Science Park, Reinforcing Hong Kong's Position as an International Health and Medical Innovation Hub

Hong Kong Science Park is home to more than 360 life sciences companies, while the number of cell and gene therapy (CGT) enterprises continues to grow, spanning frontier fields such as stem cells, gene editing, personalised cancer vaccines and CAR-T immunotherapy, and addressing diseases including cancer, heart failure and neurodegenerative disorders. HKSTP will continue to strengthen Hong Kong's position as an international health and medical innovation hub by accelerating the translation and application of more locally developed R&D outcomes for the benefit of patients, the industry and society. In doing so, it aims to make innovative therapies more accessible and enable Hong Kong to play an even greater role on the global life and health tech stage.

Hashtag: #HKSTP

The issuer is solely responsible for the content of this announcement.

Hong Kong Science and Technology Parks Corporation

Hong Kong Science and Technology Parks Corporation (HKSTP) was established in 2001 to create a thriving I&T ecosystem grooming 14 unicorns, more than 17,000 research professionals and over 2,400 technology companies from 26 countries and regions focused on developing healthtech, AI and robotics, fintech and smart city technologies, etc.

Our growing innovation ecosystem offers comprehensive support to attract and nurture talent, accelerate and commercialise innovation for technology ventures, with the I&T journey built around our key locations of Hong Kong Science Park in Pak Shek Kok, InnoCentre in Kowloon Tong and three modern InnoParks in Tai Po, Tseung Kwan O and Yuen Long realising a vision of new industrialisation for Hong Kong, where sectors including advanced manufacturing, micro-electronics and biotechnology are being reimagined.

Hong Kong Science Park Shenzhen Branch in Futian, Shenzhen plays positive roles in connecting the world and the mainland with our proximity, strengthening cross-border exchange to bring advantages in attracting global talent and allowing possibilities for the development of technology companies in seven key areas: Medtech, big data and AI, robotics, new materials, microelectronics, fintech and sustainability, with both dry and wet laboratories, co-working space, conference and exhibition facilities, and more.

Through our R&D infrastructure, startup support and enterprise services, commercialisation and investment expertise, partnership networks and talent traction, HKSTP continues to contribute in establishing I&T as a pillar of growth for Hong Kong.

More information about HKSTP is available at www.hkstp.org.

** This press release is distributed by Media OutReach Newswire through automated distribution system, for which the client assumes full responsibility. **

MANILA, PHILIPPINES - Media OutReach Newswire - 31 July 2026 - VinFast has officially launched its electric motorcycle ecosystem in the Philippines, opening 21 VinFast showrooms alongside the debut of three models, Evo, Feliz II, and Viper. The milestone marks an important step in VinFast's expansion in one of Southeast Asia's largest two-wheeler markets, bringing modern, cost-effective, and sustainable mobility solutions closer to consumers while laying the foundation for a comprehensive green mobility ecosystem in the Philippines.

Vinfast Opens 21 Electric Motorcycle Showrooms, Deepening Its Green Mobility Presence In The Philippines.
The 21 pioneer dealerships will begin operations in major cities nationwide, expanding consumer access to VinFast products and authorized services. The network is expected to grow further in the coming period, progressively expanding VinFast's presence across the Philippines.

Vinfast Opens 21 Electric Motorcycle Showrooms, Deepening Its Green Mobility Presence In The Philippines.

The simultaneous opening of 21 showrooms comes just over a month after the success of VinFast's early booking program, which attracted thousands of customers nationwide. The strong market response to VinFast's battery-swapping electric motorcycles not only demonstrates the products' appeal but also underscores the company's investment commitment and rapid expansion in the Philippines.

VinFast aims to develop its dealerships as all-in-one destinations, bringing product displays, energy solutions, and technical services together under one roof. Customers can receive personalized consultations, take test rides, experience a one-minute battery swap, explore home-charging solutions, and choose an ownership option that best suits their needs, with professional support throughout the entire journey, from initial product discovery to after-sales service.

In addition to the official showcase of the brand's first product lineup and its full range of available colors, the launch featured test rides and one-minute battery-swapping demonstrations. The brand also shared its official local pricing, battery solutions, and supporting ecosystem, including plans to deploy 30,000 battery-swapping cabinets nationwide in partnership with infrastructure providers.

Following the launch event, a series of public experience activities will take place at the new dealerships throughout August 2026. Customers will be able to see and test ride the three models, learn about battery technology and sales policies, and explore flexible ownership options. Details of the test ride program and applicable terms are available on VinFast's official website: vinfastauto.ph/en.

To celebrate the occasion, participating dealerships will introduce a variety of exclusive offers and promotional programs, providing additional benefits and value for early adopters.

Ms. Vo Thi Cam Tu, CEO of VinFast E-Scooters & E-Bikes, International Markets, said: "Opening 21 VinFast showrooms alongside the launch of our three electric motorcycle models reflects VinFast's long-term investment commitment to the Philippines. Beyond offering products that meet diverse mobility needs, we are building a comprehensive ecosystem that makes it easier for customers to access our vehicles, energy solutions, and support services throughout their ownership journey. As our electric mobility ecosystem continues to expand, we believe electric motorcycles can become an increasingly practical and convenient choice in the everyday lives of Filipinos."

Evo, Feliz II, and Viper each offer distinct characteristics designed to meet a wide range of mobility needs and riding styles. Evo combines elegant styling with everyday agility, offering a top speed of 80 km/h and a range of up to 150 km with two fully charged batteries. Feliz II emphasizes practicality and versatile performance, with a top speed of 90 km/h. Rounding out the lineup is Viper, featuring a sporty design, maximum power output of 5,200W, and a top speed of 90 km/h, aimed at younger riders who value technology and engaging riding experience.

All three models feature two under-seat battery compartments and are compatible with VinFast's battery-swapping solution, giving riders greater flexibility and convenience in everyday use. Customers can also choose between purchasing their motorcycle with batteries included or subscribing to a battery subscription plan, depending on their needs and usage patterns.

Notably, VinFast electric motorcycle owners will receive free battery swaps at public swapping stations operated by strategic partner V-Green for one year, with up to 20 swaps per month per vehicle. The models are also covered by a 4+2-year or 60,000+12,000-km warranty, whichever comes first, providing customers with greater benefits, lower operating costs, and long-term peace of mind.

VinFast's entry into the Philippine electric motorcycle market builds on its expansion across key Southeast Asian markets, following the opening of 20 electric motorcycle dealerships in Indonesia in July 2026. By steadily expanding its presence, VinFast is building out a comprehensive green mobility ecosystem across the region, making it easier for consumers to transition to smarter, more modern, and environmentally-friendly transportation solutions.

Hashtag: #VinFast

The issuer is solely responsible for the content of this announcement.

** This press release is distributed by Media OutReach Newswire through automated distribution system, for which the client assumes full responsibility. **